Myriad Genetics Q3 revenue $191.9M, up 23% YoY; raises FY2023 guidance, introduces FY2024 guidance

MYRIAD GENETICS INC

2023-Q3 EPS reported -$2.84 revenue$556,600,000

Q3 revenue $191.9M (+23% YoY); GAAP EPS -$0.75, adjusted EPS -$0.03.
Testing volume ex-SneakPeek +18% YoY; hereditary cancer +18%, prenatal +20%, GeneSight +19%.
Raised FY2023 revenue guidance to $747-753M (prev $730-750M); introduced FY2024 guidance $815-835M.
Settled Ravgen litigation for $12.75M plus contingent $21.25M; expanded credit facility to $115M.
New UnitedHealthcare contract effective Jan 1, 2024 through 2027; appointed Sam Raha COO effective Dec 11.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MYRIAD GENETICS INC reported three months ended September 30, 2023 results: revenue $191.9 million, EPS $(0.75). Guidance raised.

Period: three months ended September 30, 2023
Revenue: $191.9 million
EPS: $(0.75)
Guidance: raised
Result: reported results

Exact text from the filing

respectively. ▪ Prenatal test volumes grew 20% and 14% year-over-year, respectively, excluding contributions from the SneakPeek Early Gender DNA Test. • Third quarter revenue of $191.9 million, grew 23% year-over-year, inclusive of a $7.1 million change of estimate 1 in the current quarter versus $(5.3) million change of estimate 1 in the third quarter of 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-23-000083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.